{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:08:51Z","timestamp":1792516131361,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:p>\n                    Thyroid cancer is the most common endocrine malignancy, with rising resistance to radioactive iodine therapy in differentiated thyroid cancer (DTC).\n                    <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                    and telomerase reverse transcriptase (\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    ) promoter mutations synergistically drive recurrence and mortality in papillary thyroid cancer. This study investigates their association with radioiodine avidity loss, clinical features, and prognostic significance in Vietnamese patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). We analyzed the diagnostic and prognostic values of\n                    <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter mutations in 144 patients with DTC who underwent total thyroidectomy and received \u00b9\u00b3\u00b9I treatment from January 2021 to December 2024. The\n                    <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                    mutation was detected in 81.9% (118\/144) of cases, while the\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter mutation was found in 38.2% (55\/144).\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    mutations were more frequent in RAIR-DTC patients than in radioiodine-responsive cases, increasing the risk of radioiodine avidity loss (OR\u2005=\u20053.6,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007), while\n                    <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                    alone showed no significant impact. Coexisting\n                    <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    mutations independently elevated the risk of loss of radioiodine avidity (OR\u2005=\u20054.8,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009). Both mutations were linked to tumor size, thyroglobulin levels, recurrence\/metastasis, and higher recurrence risk, with co-mutation accelerating recurrence.\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    mutations distinguished RAIR-DTC from responsive cases (AUC\u2005=\u20050.63) and moderately predicted recurrence (AUC\u2005=\u20050.72), similar to co-mutation (AUC\u2005=\u20050.69). Postoperative recurrence-free survival was shorter in co-mutated cases (10.5 months) than in\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    -negative (11.3 months) or\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    -only (11.8 months) groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). Our study suggests that\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter mutations contribute to an increased risk of radioactive iodine treatment failure in patients with DTC. These mutations may serve as an early biomarker for radioiodine resistance.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044540","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:00:53Z","timestamp":1758574853000},"page":"e44540","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic significance of BRAF V600E and TERT promoter mutations in radioiodine resistance and recurrence of differentiated thyroid cancer"],"prefix":"10.1097","volume":"104","author":[{"given":"Le Thi Tuyet","family":"Nhung","sequence":"first","affiliation":[{"name":"103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam"},{"name":"Cancer Center, 19-8 Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghiem Xuan","family":"Hoan","sequence":"additional","affiliation":[{"name":"Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Phuong","family":"Giang","sequence":"additional","affiliation":[{"name":"Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang Trung","family":"Dung","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi","family":"Phuong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo Thi Minh","family":"Hanh","sequence":"additional","affiliation":[{"name":"Department of Pathology, 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Van","family":"Khanh","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo Thu","family":"Hang","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Ngoc","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, 108 Military Central Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8810","authenticated-orcid":false,"given":"Hoang Van","family":"Tong","sequence":"additional","affiliation":[{"name":"Vietnamese-German Center for Medical Research (VG-CARE), 108 Military Central Hospital, Hanoi, Vietnam"},{"name":"Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam"},{"name":"Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250928","doi-asserted-by":"crossref","first-page":"101703","DOI":"10.1016\/j.beem.2022.101703","article-title":"Radioiodine therapy in the different stages of differentiated thyroid cancer.","volume":"37","author":"Valerio","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R3-20250928","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20250928","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","article-title":"Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.","volume":"6","author":"Worden","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"R5-20250928","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers15020413","article-title":"Effect of having concurrent mutations on the degree of aggressiveness in patients with thyroid cancer positive for TERT promoter mutations.","volume":"15","author":"Alohali","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R6-20250928","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality.","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"R7-20250928","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S0016672316000057","article-title":"Molecular genetics of thyroid cancer.","volume":"98","author":"Rebasmall Yi","year":"2016","journal-title":"Genet Res (Camb)"},{"key":"R8-20250928","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20250928","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"R10-20250928","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/erc.1.0978","article-title":"BRAF mutation in thyroid cancer.","volume":"12","author":"Xing","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R11-20250928","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1126\/science.290.5489.138","article-title":"Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.","volume":"290","author":"Nikiforova","year":"2000","journal-title":"Science"},{"key":"R12-20250928","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0092-8674(04)00053-4","article-title":"Tracking telomerase.","volume":"116","author":"Greider","year":"2004","journal-title":"Cell"},{"key":"R13-20250928","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrg1656","article-title":"Telomeres and human disease: ageing, cancer and beyond.","volume":"6","author":"Blasco","year":"2005","journal-title":"Nat Rev Genet"},{"key":"R14-20250928","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ncb985","article-title":"Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.","volume":"5","author":"Smith","year":"2003","journal-title":"Nat Cell Biol"},{"key":"R15-20250928","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-5793(04)00356-4","article-title":"On the road to immortality: hTERT upregulation in cancer cells.","volume":"564","author":"Janknecht","year":"2004","journal-title":"FEBS Lett"},{"key":"R16-20250928","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1093\/nar\/gkq370","article-title":"InTERTpreting telomerase structure and function.","volume":"38","author":"Wyatt","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R17-20250928","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer.","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"R18-20250928","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer.","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"R19-20250928","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach.","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R21-20250928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R22-20250928","doi-asserted-by":"crossref","first-page":"965212","DOI":"10.1155\/2013\/965212","article-title":"Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.","volume":"2013","author":"Pellegriti","year":"2013","journal-title":"J Cancer Epidemiol"},{"key":"R23-20250928","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2265.2007.03008.x","article-title":"Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.","volume":"68","author":"Mian","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R24-20250928","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","article-title":"Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.","volume":"67","author":"Yang","year":"2020","journal-title":"Endocrine"},{"key":"R25-20250928","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients.","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R26-20250928","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer.","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"R27-20250928","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1097\/RLU.0000000000002142","article-title":"BRAFV600E mutation does not significantly affect the efficacy of radioiodine therapy in patients with papillary thyroid carcinoma without known distant metastases.","volume":"43","author":"Shen","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R28-20250928","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer.","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"R29-20250928","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"R30-20250928","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.","volume":"33","author":"Xing","year":"2015","journal-title":"J Clin Oncol"},{"key":"R31-20250928","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3803\/EnM.2020.304","article-title":"Mechanisms of TERT reactivation and its interaction with BRAFV600E.","volume":"35","author":"Song","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R32-20250928","doi-asserted-by":"crossref","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis.","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:02:37Z","timestamp":1759046557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":30,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044540","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}